Imaging
Embarking on healthcare technology career after leaving his home as a refugee during his teenage years, Yousif is passionate about making a difference. He reflects on an apprenticeship in which he has worked alongside technology innovators and the hospital teams that put solutions into practice for patient care. When Yousif saw an opportunity advertised to [...]
Oxford University Hospitals NHS Foundation Trust (OUH), in partnership with Ergéa UK, has completed a major upgrade to diagnostic imaging services at John Radcliffe Hospital, marking a significant milestone in OUH’s long-term programme to modernise radiology equipment, enhance patient care, and improve clinical outcomes. Delivered through a Managed Equipment Service (MES) agreement with Ergéa UK, [...]
By Roy Wills, VP, Head of Healthcare Business and Partnerships, Intellias Medical imaging has always been at the heart of modern medicine – the lens through which clinicians see what the human eye cannot. Yet as imaging has evolved from grainy 2D pictures to ultra-high-resolution tomographic images, it’s also become a data-intensive discipline. [...]
Scientists have completed full-body scans of 100,000 people in what is believed to be the world’s largest body imaging study. The decade-long initiative has produced one billion anonymised images showing internal organs, blood vessels, bones and joints, which researchers can now use to explore how ageing and disease develop. Each participant contributed around 12,000 images, [...]
The doors have officially opened to a new radiotherapy centre in Milton Keynes, sparing hundreds of cancer patients each year from a lengthy 70-mile round trip to Oxford for vital treatment. OUH Radiotherapy @ Milton Keynes is run by an expert multidisciplinary team from Oxford University Hospitals NHS Foundation Trust (OUH) and is linked to [...]
Qureight Ltd, a Core Imaging Laboratory developing deep-learning image analytics, and Vicore Pharma, a clinical-stage biopharmaceutical company, have announced the implementation of Qureight’s Core Imaging Platform within the global Phase 2b ASPIRE trial investigating buloxibutid in patients with idiopathic pulmonary fibrosis (IPF). ASPIRE is an ongoing global 52-week Phase 2b, randomised, double-blind, placebo-controlled, parallel-group clinical [...]
